Royalty Pharma (RPRX) reported Q4 net income Tuesday of $208 million, down from $494 million a year earlier.
Comparable analyst estimates were not available.
Total income and other revenues ended Dec. 31 were $594 million, down from $596 million a year earlier.
Analysts surveyed by FactSet expected $687 million.
As of Dec. 31, the company said it had $929 million in cash and cash equivalents.
Shares of the UK biopharmaceutical company were up more than 2% in Tuesday's premarket activity.
Price: 32.45, Change: +0.73, Percent Change: +2.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.